- Apr 19, 2018 -
The export of pharmaceutical intermediates is much less restricted by importing countries than for apis and preparations.
In recent years, many big pharmaceutical companies in the United States and Europe have taken into account the cost savings and environmental requirements.
The production of its pharmaceutical intermediates is gradually transferred to developing countries, or more from developing countries.
Medical intermediates. This has brought great business opportunities to our pharmaceutical intermediates. Experts think
In order to, due to years of accumulated technical advantages and future pharmaceutical market demand, China pharmaceutical intermediates industry.
There is great potential for development. In particular, sulfonamides, tetracycline, analgin and other commodities are me.
The country went out earlier. With the passage of time, China's pharmaceutical intermediates develop rapidly, from the present part.
We have an advantage in the global market share. VC, penicillin, acetaminophen,
Paracetamol and citric acid account for more than 60% of the world's share, amoxicillin, ceftriaxone, ibuprofen,
Aspirin is an influential product category in the world. In product classification, anti - infective medicine, maintenance.
Su, antipyretic analgesic drugs, amino acids and so on are China's export - type API series, accounting for the total amount of raw drug exports.
More than 90%, the corresponding intermediate domestic demand is also larger. The experts also warn about pharmaceutical intermediates.
Production enterprises: as the situation progresses, the research and production of pharmaceutical intermediates should also be adjusted. Experts think
For the changes in the disease spectrum will create new fields in the pharmaceutical market, and the corresponding pharmaceutical intermediates will also change.
So there are new opportunities. At the seminar, experts speculated that the most common disease in 2010 was sperm.
God's disease, menopause, erectile dysfunction, obesity, cardiovascular and cerebrovascular diseases, cancer, chronic sinuses.
Inflammation, migraines, diabetes mellitus, senile disease, fatal infection, etc., this is bound to welcome the related drug intermediates.Increased demand.